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Summary
Background:  Abdominal  aortic  aneurysm  (AAA)  expansion  is  characterized  by  chronic  inﬂam-
matory cell  inﬁltration  and  extracellular  matrix  degradation.  High-mobility  group  box  1
protein (HMGB1)  is  one  of  the  damage-associated  molecular  pattern  molecules  derived  from
injured/necrotic  and  activated  inﬂammatory  cells.  We  investigated  the  expression  of  HMGB1  in
human AAA  and  mouse  experimental  AAA.  Then,  we  evaluated  the  effect  of  HMGB1  blockade
on AAA  formation  in  the  mouse  model.
Methods  and  results:  Human  AAA  samples  showed  increased  HMGB1  expression  compared  with
normal aortic  wall.  In  a  mouse  CaCl2-induced  AAA  model,  the  expression  of  HMGB1  was  increased
compared  with  that  in  sham,  and  was  positively  correlated  with  matrix  metalloproteinase
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(MMP)-2  and  MMP-9  activity.  We  a
control antibody  (AAA/C)  to  AAA  
neutralizing  anti-HMGB1  antibody
tation. HMGB1  blockade  markedl
activity in  aneurysmal  tissue.  The
was reduced  in  AAA/anti-H  compa
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mouse experimental  AAA.  HMGB1
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IgY  antibody  (AAA/C).  To  prepare  neutralizing  anti-HMGB1
antibody,  IgY  class  antibody  from  the  egg  yolk  of  HMGB1-
immunized  hens  was  isolated  and  puriﬁed  [14,18].  Thentroduction
hronic  inﬂammation  of  the  aortic  wall  has  been  implicated
n  the  development,  expansion,  and  rupture  of  abdomi-
al  aortic  aneurysm  (AAA)  [1—6]. Inﬂammatory  cells  in  the
edia  and  adventitia  are  signiﬁcant  sources  of  cytokines
hat  stimulate  proteolytic  enzymes  such  as  matrix  metal-
oproteinases  (MMPs)  [3,7,8].  MMPs  mediate  fragmentation
f  extracellular  matrix  (ECM)  elastin  ﬁbers  with  a  reduction
f  their  concentration  in  ECM,  which  is  the  pathologic  hall-
ark  of  AAA  [7—9]. However,  the  molecular  mechanism  that
aintains  the  inﬂammatory  response  and  MMP  activation  in
neurysmal  tissue  is  still  not  fully  understood.
High-mobility  group  box  1  protein  (HMGB1)  was  orig-
nally  identiﬁed  as  a  nonhistone  DNA-binding  nuclear
rotein  produced  by  nearly  all  cell  types  [10]. It  stabilizes
ucleosomes  and  enables  bending  of  DNA,  which  facili-
ates  gene  transcription.  Recently,  it  has  been  clariﬁed
hat  HMGB1  is  released  passively  from  injured/necrotic
ells,  and  is  actively  secreted  by  inﬂammatory  cells  in
esponse  to  proinﬂammatory  cytokines  [10—12]. As  extra-
ellular  HMGB1  itself  can  elicit  proinﬂammatory  responses
y  increasing  the  expression  of  proinﬂammatory  cytokines
10,13],  HMGB1  participates  in  perpetuation  of  inﬂamma-
ion  and  has  been  reported  to  play  an  essential  role  in
he  pathogenesis  of  inﬂammatory  diseases  such  as  sep-
is,  rheumatoid  arthritis,  and  atherosclerosis  [10,12,14—18].
arious  stimuli  have  been  linked  to  the  inﬂammation
bserved  in  AAA,  including  oxidative  stress  and  proin-
ammatory  cytokines  [2,3,19].  These  stimuli  also  activate
MGB1  expression  in  macrophages,  monocytes,  and  smooth
uscle  cells  (SMCs)  [10,12,16,17,20].  Increased  HMGB1
xpression  is  also  reported  to  be  linked  to  MMP  activa-
ion.  A  previous  study  demonstrated  that  blockade  of  HMGB1
uppressed  inﬂammatory  cell  inﬁltration  and  MMP-9  induc-
ion  during  ischemia/reperfusion  injury  [21]. Additionally,
MGB1  directly  stimulated  the  production  of  MMPs  in  vitro
17,22,23]. The  importance  of  HMGB1  in  inﬂammation  and
MP  activation  led  us  to  hypothesize  that  HMGB1  might  play
 key  role  in  the  progression  of  AAA  through  the  persistence
f  inﬂammation  and  ECM  degradation.
To  test  this  hypothesis,  we  ﬁrst  examined  the  expres-
ion  level  and  distribution  of  HMGB1  in  aortic  tissue  in  both
uman  and  experimental  AAA.  We  then  evaluated  whether
lockade  of  HMGB1  could  attenuate  aneurysm  formation  in
 mouse  AAA  model.
d
a
a
odministered  neutralizing  anti-HMGB1  antibody  (AAA/anti-H)  or
mice  subcutaneously  every  3  days  for  6  weeks.  Treatment  with
 suppressed  AAA  formation,  and  attenuated  elastin  fragmen-
y  reduced  the  number  of  macrophages  and  MMP-2  and  MMP-9
 mRNA  level  of  tumor  necrosis  factor-  and  CD68  in  the  aorta
red  with  AAA/C.
1  level  in  aneurysmal  tissue  was  observed  in  human  AAA  and
 blockade  in  a  mouse  AAA  model  reduced  AAA  progression,  in
on  of  macrophages  and  MMPs  activity.  These  ﬁndings  suggest  a
pathogenesis  of  AAA.
ology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
aterials and methods
linical  study  protocol
or  determination  of  serum  HMGB1  level,  serum  was  col-
ected  from  40  patients  with  atherosclerosis-associated  AAA
ho  were  admitted  to  Keio  University  Hospital.  A  diagnosis
f  AAA  was  made  on  the  basis  of  abdominal  computed  tomog-
aphy  showing  dilatation  of  the  abdominal  aorta,  with  a
iameter  ≥5  cm.  The  study  population  consisted  of  patients
ho  had  survived  a  ruptured  aorta  (n  =  6)  and  patients
n  whom  the  diagnosis  had  been  made  through  computed
omography  performed  for  other  reasons  (n  =  34).  There  was
o  patient  with  recent  infection,  active  inﬂammatory  disor-
er,  malignancy,  collagen  disease,  or  chronic  renal  failure.
he  shoulders  (between  the  edge  and  the  maximal  side)  of
he  AAA  were  obtained  from  patients  during  elective  surgical
epair  of  AAA  (n  =  5).  Control  aortic  samples  were  obtained
rom  autopsy  specimens  of  patients  who  had  died  of  unre-
ated  causes  (n  =  5).  This  clinical  investigation  was  approved
y  the  institutional  medical  ethical  committee  and  con-
ucted  according  to  the  ethical  guidelines  outlined  in  the
eclaration  of  Helsinki.
ouse  model  of  experimental  AAA
e  induced  AAA  in  8-week  old  mice  (C57BL/6J)  by  periaortic
pplication  of  0.5  M  calcium  chloride  (CaCl2) as  described
reviously,  with  minor  modiﬁcations  [24,25]. The  sham
roup  received  saline  instead  of  CaCl2. To  determine  HMGB1
xpression,  mice  were  killed  6  weeks  after  operation  for
istological  (n  =  6)  and  protein  analyses  (n  = 6).
In  the  HMGB1  blockade  study,  AAA  mice  were  ran-
omly  assigned  to  two  groups:  (1)  neutralizing  polyclonal
hicken  IgY  anti-HMGB1  antibody  (10  mg/kg/day,  donated
y  Shino-Test  Corporation,  Sagamihara,  Japan)  administered
ubcutaneously  24  h  after  operation  and  subsequently  every
 days  for  6  weeks  (AAA/anti-H),  and  (2)  control  chickenosage  of  neutralizing  anti-HMGB1  antibody  was  determined
ccording  to  a  previous  study  showing  improved  survival  in
 rodent  sepsis  model  [14]. Mice  were  killed  6  weeks  after
peration  for  histological  (n  =  6),  mRNA  (n  =  6),  and  protein
o
b
p
i
a
I
R
H
H
m
p
E
a
(
r
o
(
m
a
i
w
(
n
y
s
p
b
r
d
A
H
e
I
i
s
a
i
i
i
(
E
M
m
c
i
m
w
iHMGB1protein  blockade  suppresses  development  of  AAA  
analyses  (n  =  6).  All  procedures  were  performed  in  accor-
dance  with  the  Keio  University  animal  care  guidelines.
Histological  study
For  histological  analyses,  mice  were  killed  by  an  over-
dose  of  pentobarbital  and  perfusion-ﬁxed  with  a  mixture
of  10%  formaldehyde  in  phosphate  buffered  saline  at  phys-
iological  perfusion  pressure.  We  excised  the  abdominal
aortas,  photographed  them  to  determine  the  external
diameter  and  used  them  for  histological  analyses.  Parafﬁn-
embedded  cross-sections  (6  m  thick)  were  stained  with
hematoxylin—eosin  (HE)  and  elastica  van  Gieson  (EVG).
Immunohistochemical  studies  were  performed  using  the
antibodies  against  HMGB1  (Shino-Test  Corporation)  and
Mac-3  (BD  Pharmingen,  San  Jose,  CA,  USA)  as  described  pre-
viously  [18,25].
Western  blotting
Frozen  tissue  was  homogenized  in  cell  lysis  buffer  (Cell  Sig-
naling,  Danvers,  MA,  USA)  containing  1%  Triton  X-100  and
protease  inhibitors.  Western  blot  analysis  with  rabbit  poly-
clonal  HMGB1  antibody  (Shino-Test  Corporation)  was  carried
out  as  previously  described  [18].
Real-time  quantitative  reverse  transcriptase
polymerase  chain  reaction
Total  RNA  was  isolated  by  acid—phenol  extraction  in  the
presence  of  chaotropic  salts  (TRIzol,  Invitrogen,  Carlsbad,
CA,  USA)  and  subsequent  isopropanol—ethanol  precipitation
as  described  previously  [18,25].
Real-time  quantitative  reverse  transcriptase  polymerase
chain  reaction  was  carried  out  as  described  previ-
ously  [18,25].  Gene  expression  of  the  housekeeping  gene
glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH)  was
used  for  normalization.  Monocyte  chemoattractant  protein
(MCP)-1,  tumor  necrosis  factor  (TNF)-, CD68,  and  GAPDH
assays  were  purchased  as  pre-optimized  kits  (‘‘TaqMan’’
probe;  Applied  Biosystems,  Carlsbad,  CA,  USA:  Catalogue
number,  Mm99999056  m1  [MCP-1],  Mm00443258  m1  [TNF-
],  Mm00839636  g1  [CD68]).
Zymography
Equal  amounts  of  10  g  of  protein  were  electrophoresed
on  10%  Zymogram  (gelatin)  Gel  (Invitrogen).  After  elec-
trophoresis,  the  gels  were  renatured  in  renaturing  buffer;
50  mM  Tris—HCl  containing  100  mM  NaCl  and  2.5%  Triton
X-100.  They  were  then  incubated  with  developing  buffer;
50  mM  Tris—HCl  containing  10  mM  CaCl2.  The  gels  were
stained  with  Coomassie  Brilliant  Blue  (Invitrogen),  and
destained  in  water.
Statistical  analysesCategorical  variables  were  compared  between  groups  using
chi-squared  test  (with  Yates’  continuity  correction).  All
continuous  data  are  expressed  as  mean  value  ±  SD  unless
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therwise  stated.  Statistical  signiﬁcance  of  differences
etween  multiple  groups  was  determined  using  ANOVA  and
ost  hoc  analysis  with  Bonferroni  test.  Statistical  signif-
cance  was  deﬁned  as  a  p  value  of  <  0.05.  All  statistical
nalyses  were  performed  using  SPSS  15.0  for  Windows  (SPSS
nc.,  Chicago,  IL,  USA).
esults
MGB1  expression  in  human  AAA
E  staining  showed  extensive  atherosclerotic  plaque  and
arked  inﬁltration  of  inﬂammatory  cells  in  human  AAA  sam-
les  compared  with  control  samples  (Fig.  1A,  D,  and  G).
VG  staining  showed  that  AAA  walls  had  medial  disruption  or
ttenuation  and  degradation  of  the  wavy  structure  of  elastin
Fig.  1B,  E,  and  H).  Immunohistochemical  staining  for  HMGB1
evealed  that  HMGB1  expression  was  enhanced  in  all  layers
f  the  AAA  aortic  wall,  especially  in  the  media  and  adventitia
Fig.  1C,  F,  and  I).  HMGB1  was  highly  expressed  in  inﬂam-
atory  cells  within  the  adventitia  (Fig.  1J),  media,  and
therosclerotic  plaque  (Fig.  1K).  HMGB1  was  also  expressed
n  SMCs  and  endothelial  cells  in  AAA  tissue  (Fig.  1L  and  M).
Serum  HMGB1  level  was  signiﬁcantly  higher  in  patients
ith  ruptured  AAA  than  in  those  with  nonruptured  AAA
4.9  ±  3.4  ng/ml  vs.  1.9  ±  2.9  ng/ml,  p  =  0.01).  There  were
o  signiﬁcant  differences  in  age  (65  ±  13  years  vs.  64  ±  13
ears,  p  =  0.63),  sex  (male/female,  6/0  vs.  31/3,  p  =  0.45),
moking  (50%  vs.  38%,  p  =  0.35),  hypertension  (83%  vs.  65%,
 =  0.11),  dyslipidemia  (33%  vs.  41%,  p  =  0.96),  and  dia-
etes  mellitus  (17%  vs.  21%,  p  =  0.98)  between  patients  with
uptured  AAA  and  nonruptured  AAA.  The  maximum  AAA
iameter  was  greater  in  ruptured  AAA  than  in  nonruptured
AA  (6.9  ±  1.0  mm  vs.  5.8  ±  1.2  mm,  p  =  0.03).
MGB1  expression  and  MMP  activity  in
xperimental  AAA
n  an  experimental  model  of  AAA,  HMGB1  expression  was
ncreased  in  aneurysmal  aorta  relative  to  non-aneurysmal
ham  (Fig.  2A).  MMP-2  and  MMP-9  activity  also  increased  in
neurysmal  tissue  (Fig.  2B)  and  showed  a  signiﬁcantly  pos-
tive  correlation  with  HMGB1  level  (Fig.  2C).  In  AAA  mice,
mmunohistochemical  staining  of  HMGB1  was  enhanced  in
nﬁltrating  inﬂammatory  cells,  SMCs,  and  endothelial  cells
Fig.  2D—G).
ffect  of  HMGB1  blockade  in  experimental  AAA
orphometric  analyses  of  the  aorta  showed  that  the  maxi-
um  aortic  diameter  was  signiﬁcantly  smaller  in  AAA/anti-H
ompared  with  AAA/C  (Fig.  3A—D).  HE  staining  showed  that
nﬁltration  of  inﬂammatory  cells  in  the  aortic  wall  was  more
arked  in  AAA/C  than  in  sham-operated  mice.  However,  it
as  attenuated  by  HMGB1  blockade  (Fig.  4A—C).  EVG  stain-
ng  showed  that  the  aorta  of  AAA/C  had  thinning  of  the
edial  layer  and  disruption  of  the  elastic  lamellae,  which
howed  a  ﬂattened  appearance  instead  of  the  wavy  appear-
nce  observed  in  sham.  Neutralizing  anti-HMGB1  antibody
reatment  partially  restored  the  wavy  structure  of  the
302  T.  Kohno  et  al.
Figure  1  Hematoxylin—eosin  staining  (A,  D,  and  G),  elastic  van  Gieson  staining  (B,  E,  and  H),  and  high-mobility  group  box  1
protein (HMGB1)  immunostaining  (C,  F,  and  I)  of  the  human  aorta.  In  the  abdominal  aortic  aneurysm  (AAA),  HMGB1  was  expressed  in
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[nﬂammatory cells  (J  and  K),  smooth  muscle  cells  (L),  and  endo
, adventitia;  m,  media;  i,  intima.
lastic  lamellae  (Fig.  4D—F).  The  increased  number  of  Mac-
-positive  macrophages  in  aneurysmal  tissue  was  attenuated
y  HMGB1  blockade  (Fig.  4G—J).  Neutralizing  anti-HMGB1
ntibody  treatment  diminished  AAA-induced  mRNA  expres-
ion  of  TNF- and  CD68  in  aneurysmal  tissue.  Although  the
ifference  was  not  statistically  signiﬁcant,  mRNA  expression
f  MCP-1  in  AAA/anti-H  was  less  than  half  that  in  AAA/C
Fig.  5A—C).  Zymographic  activity  of  MMP-2  and  MMP-9  was
levated  in  AAA/C  compared  to  sham.  Mice  in  AAA/anti-
 exhibited  signiﬁcantly  lower  MMP-2  and  MMP-9  activity
ompared  with  that  in  AAA/C  (Fig.  5D  and  E).
iscussion
n  this  study,  we  demonstrated  that  HMGB1  expression
as  increased  in  human  aneurysmal  tissue.  In  an  experi-
ental  study  using  a  mouse  CaCl2-induced-AAA  model,  we
lso  found  increased  aneurysmal  HMGB1  expression,  which
as  positively  correlated  with  MMP-2  and  MMP-9  activity.
lockade  of  HMGB1  by  neutralizing  anti-HMGB1  antibody
ttenuated  the  development  of  AAA,  in  association  with
educed  inﬁltration  of  macrophages  and  MMP  activity.  These
ndings  suggested  that  HMGB1  plays  a  signiﬁcant  role  in  the
i
r
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aal  cells  (M).  Scale  bar  indicates  500  m  (A—I)  and  50  m  (J—M).
athogenesis  of  AAA  by  affecting  vascular  inﬂammation  and
CM  degradation.
HMGB1  was  recently  shown  to  act  as  a danger  sig-
al,  mediating  crosstalk  among  injured  cells,  activated
nﬂammatory  cells,  and  relatively  healthy  cells  around
amaged  tissue,  which  leads  to  the  initiation  and  perpet-
ation  of  inﬂammation  [10—13,23].  Previous  studies  showed
hat  HMGB1  contributes  to  inﬂammation  in  atherosclerosis
15—17].  Kalinina  et  al.  demonstrated  that  the  number  of
MGB1-producing  macrophages  increased  during  the  devel-
pment  and  progression  of  atherosclerotic  lesions  [15].
lthough  chronic  inﬂammation  contributes  to  the  patho-
enesis  of  both  atherosclerosis  and  AAA,  it  has  become
lear  that  aneurysms,  once  thought  to  be  a  form  of
therosclerosis,  have  a  distinct  pathogenesis  from  that  of
tenotic  vascular  disease.  Atherosclerotic  plaques  are  pri-
arily  characterized  by  intimal  inﬁltration  of  inﬂammatory
ells.  In  contrast,  aneurysmal  segments  are  character-
zed  by  inﬂammatory  cell  accumulation  primarily  in  the
edia  and  adventitia  at  all  stages  of  disease  progression
3,4].  We  showed  that  HMGB1  expression  was  increased
n  macrophages  within  atherosclerotic  plaque.  However,
egardless  of  atherosclerosis  severity,  intense  HMGB1  stain-
ng  in  inﬂammatory  cells  and  SMCs  within  the  media  and
dventitia  was  observed  in  aneurysmal  tissue.  Therefore,  it
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Figure  2  Expression  of  high-mobility  group  box  1  protein  (HMGB1)  (A)  and  activity  of  matrix  metalloproteinase  (MMP)-2  and  MMP-9
(B) in  aneurysmal  tissue  in  mouse  abdominal  aortic  aneurysm  (AAA)  model.  Correlation  between  HMGB1  expression  and  MMP  activity
(C). Open  circles,  sham;  closed  circles,  AAA.  Representative  low-power  micrographs  showing  HMGB1  immunohistochemical  staining
in mouse  AAA  model  (D).  HMGB1  staining  showed  that  HMGB1  protein  was  seen  in  inﬁltrating  inﬂammatory  cells  (E),  smooth  muscle
cells (F),  and  endothelial  cells  (G)  in  mouse  AAA  tissue  (high-power  views  of  the  portion  indicated  by  square  in  [D]).  Scale  bar
indicates 100  m  (D)  and  20  m  (E—G).  Data  are  mean  ±  SEM.  *p  <  0.05  vs.  Sham.
Figure  3  Effects  of  high-mobility  group  box  1  protein  (HMGB1)  blockade  on  development  of  abdominal  aortic  aneurysm  (AAA).
Representative  macroscopic  appearance  of  the  aorta  in  sham-operated  mouse  (Sham:  A)  and  AAA  mouse  treated  with  control
(AAA/C: B)  or  neutralizing  anti-HMGB1  antibodies  (AAA/anti-H:  C).  Graph  shows  the  diameter  of  the  abdominal  aorta  6  weeks  after
operation (D).  Data  are  mean  ±  SEM.  *p  <  0.05  vs.  Sham. †p  <  0.05  vs.  AAA/C.
304  T.  Kohno  et  al.
Figure  4  Hematoxylin—eosin  (HE),  elastic  van  Gieson  (EVG),  and  Mac-3  staining  of  aortic  wall  of  sham-operated  mice  (Sham:  A,
D, and  G)  and  abdominal  aortic  aneurysm  (AAA)  mice  treated  with  control  (AAA/C:  B,  E,  and  H)  or  neutralizing  anti-high-mobility
g  show
D
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m
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aroup box  1  protein  antibodies  (AAA/anti-H:  C,  F,  and  I).  Graph
ata are  mean  ±  SEM.  *p  <  0.05  vs.  Sham. †p  <  0.05  vs.  AAA/C.s  likely  that  increased  HMGB1  expression  in  the  media  and
dventitia  might  be  related  to  the  provocation  of  inﬂam-
atory  response  that  is  required  for  the  development  of
AA.
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igure  5  Effect  of  high-mobility  group  box  1  protein  (HMGB1)  bloc
ractant protein  (MCP)-1  (B),  and  CD68  gene  expression  (C),  and  
n aortic  wall  of  sham-operated  mice  and  abdominal  aortic  aneur
nti-HMGB1 antibodies  (AAA/anti-H).  Data  are  mean  ±  SEM.  *p  <  0.05s  Mac-3-positive  cells  in  a  ﬁeld  (J).  Scale  bar  indicates  50  m.Although  nonsurgical  treatment  for  AAA  is  much  awaited,
ew  options  are  available  because  its  molecular  pathogene-
is  remains  elusive  [2,24]. We  showed  that  HMGB1  blockade
esulted  in  attenuation  of  AAA  progression.  Interestingly,  the
kade  on  tumor  necrosis  factor  (TNF)-  (A),  monocyte  chemoat-
matrix  metalloproteinase  (MMP)-2  (D)  and  MMP-9  activity  (E)
ysm  (AAA)  mice  treated  with  control  (AAA/C)  or  neutralizing
 vs.  Sham. †p  <  0.05  vs.  AAA/C.
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[HMGB1protein  blockade  suppresses  development  of  AAA  
expression  of  an  HMGB1  receptor,  receptor  for  advanced  gly-
cation  end  products  (RAGE),  was  also  upregulated  in  AAA
tissue,  and  RAGE  gene  knockout  reduced  the  incidence  of
AAA  through  inhibition  of  MMP-9  activity  [26]. Additionally,
HMGB1-induced  signaling  through  RAGE  led  to  activation  of
the  nuclear  factor  (NF)-B pathway,  and  inhibition  of  NF-B
also  attenuated  aneurysmal  dilatation  [10,27].  Taking  these
ﬁndings  together,  HMGB1  could  be  an  upstream  target  for
therapeutic  intervention  in  AAA.
Degradation  of  ECM  by  MMPs  has  been  reported  to
be  an  important  contributor  to  the  pathogenesis  of  AAA
[1—3,7—9].  Macrophage-derived  MMP-9  and  interstitial  cell-
derived  MMP-2  work  in  concert  toward  the  development  of
AAA  [8].  We  showed  that  HMGB1  was  localized  in  inﬂam-
matory  cells  and  SMCs  in  aneurysmal  tissue,  similar  to  the
localization  of  MMPs.  We  also  showed  that  HMGB1  expres-
sion  was  positively  correlated  with  MMPs  activity,  and  HMGB1
blockade  attenuated  increased  activity  of  MMPs  in  an  exper-
imental  AAA  model,  suggesting  that  HMGB1  may  affect
AAA  formation,  at  least  in  part,  by  activation  of  MMPs.
Although  this  study  does  not  clarify  the  precise  mechanism
of  MMPs  activation  by  HMGB1,  there  might  be  two  possible
mechanisms.  The  ﬁrst  is  that  HMGB1  could  enhance  MMP
activity  in  aneurysmal  tissue  through  increased  macrophage
recruitment.  The  second  is  that  HMGB1  can  directly  upregu-
late  MMP  expression.  Recent  studies  showed  that  addition
of  HMGB1  causes  MMP-2  and  MMP-9  upregulation  in  vitro
[17,22,23].  Advanced  glycation  end  products  and  S100A12,
another  RAGE  ligand,  also  directly  induce  the  production  of
MMP-9  in  macrophages  and  that  of  MMP-2  in  SMCs,  respec-
tively  [26,28].  HMGB1  might  activate  MMPs  in  aneurysmal
tissue  through  several  mechanisms.
Elevated  levels  of  various  plasma  markers  of  inﬂamma-
tion  have  been  reported  in  patients  presenting  with  ruptured
AAA  as  compared  with  nonruptured  AAA  [5].  We  demon-
strated  that  the  serum  HMGB1  level  was  elevated  in  patients
with  ruptured  AAA.  The  design  of  our  studies  cannot  exclude
the  possibility  that  the  increase  in  HMGB1  level  is  a  con-
sequence,  rather  than  a  predictor,  of  rupture.  However,
their  use  in  conjunction  with  clinical  evaluation  may  prove
a  valuable  indicator  of  impending  or  established  aneurysm
rupture.
The  present  study  has  some  limitations.  First,  the  num-
ber  of  clinical  study  participants  was  limited;  therefore,
the  statistical  power  might  not  be  adequate  to  detect
any  negative  data.  Second,  we  do  not  have  any  data  of
serum  HMGB1  level  in  healthy  controls.  A  large  number
of  circulating  markers  of  inﬂammation  have  been  assessed
for  association  with  cardiovascular  diseases  including  AAA
[2,29—31].  A  recent  clinical  study  also  showed  that  the
aneurysm  itself  is  a  source  of  elevated  proinﬂammatory
cytokines  in  serum  [5,6]. To  investigate  whether  serum
HMGB1  could  be  elevated  in  patients  with  AAA  compared  to
control  subjects  might  be  worthwhile,  and  further  studies
are  needed  to  clarify  the  possibility  of  serum  HMGB1  level
as  a  diagnostic  marker  of  AAA  development  and  progres-
sion.
In  conclusion,  the  present  study  demonstrated  ele-
vated  HMGB1  expression  in  human  and  mouse  experimental
AAA.  HMGB1  blockade  attenuated  AAA  progression  through
a  decrease  in  macrophage  inﬁltration  and  MMP  activ-
ity,  suggesting  that  HMGB1  acts  as  a  critical  mediator  of
[305
nﬂammation  and  connective  tissue  remodeling  in  AAA.  The
dentiﬁcation  of  involvement  of  HMGB1  in  the  pathogenesis
f  AAA  might  provide  a  new  target  for  therapeutic  interven-
ion.
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